Johnson & Johnson sued the U.S. Health and Human Services Department on Tuesday, accusing the agency of blocking its plan to ...

The rebate game played by drug makers and pharmacy benefit managers limits optimal biosimilar competition. As a result, U.S.

This includes large pharmacy chains and pharmacy benefit managers, leading to abuses that undermine patient benefits. Also ...

The active ingredient in Stelara is ustekinumab. (An active ingredient is what makes a drug work.) The drug comes as a liquid solution you receive as a subcutaneous injection (an injection under ...

Before injecting Stelara for the first time, talk with your doctor. They’ll show you how to inject the drug safely and help determine which injection site is best for you. Subcutaneous ...

Companies in the multi-billion dollar psoriasis market are vying to be the next standard of treatment, and a flood of new data from three drugs showing them superior to Humira and Stelara.

Johnson & Johnson has sued a U.S. government agency over a closely watched dispute focusing on payment methods for some ...

The New Jersey-based drugmaker is trying to get the courts’ backing to pay hospitals rebates for two drugs in the 340B drug ...

Johnson & Johnson files suit against HHS over 340B program, proposing hospitals pay full price upfront for drugs and receive ...

but J&J in August proposed a plan that would require disproportionate share hospitals to buy its blood thinner drug Xarelto ...

Experts predict that physicians may favour emerging biosimilar versions of Stelara over more effective originator IL-23 drugs.

The company filed a lawsuit asking for a federal court’s permission to change when it gives lucrative drug discounts to ...